Are Medical Stocks Lagging AlloVir (ALVR) This Year?

Group 1 - AlloVir, Inc. (ALVR) has shown a year-to-date return of approximately 4.4%, outperforming the Medical sector average return of about -0.9% [2][3] - The Zacks Consensus Estimate for ALVR's full-year earnings has increased by 57.9% in the past quarter, indicating improved analyst sentiment and a more positive earnings outlook [2] - AlloVir, Inc. currently holds a Zacks Rank of 2 (Buy), suggesting it is positioned to outperform the broader market in the near term [1][2] Group 2 - AlloVir, Inc. is part of the Medical - Drugs industry, which consists of 192 individual stocks and is currently ranked 94 in the Zacks Industry Rank [3] - The Medical - Drugs industry has experienced a year-to-date loss of about -0.9%, indicating that ALVR is performing better than its industry peers [3] - In comparison, Arcutis Biotherapeutics, Inc. (ARQT), another stock in the Medical sector, has achieved a year-to-date return of 64.1% and also holds a Zacks Rank of 2 (Buy) [2][3]